RxDoctor Payments Data

Tyler Emley, MD

Urology · Rensselaer, INNPI 1407989932

Payments from drug & device makers

$8,532in general payments, 2019–2025

Across 427 payments — averaging $19.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$1K
  • Johnson & Johnson$828
  • Sumitomo Pharma America, Inc.$827
  • Endo Pharmaceuticals Inc.$536
  • AbbVie$489
  • Bayer$456
  • plus $4K from 49 others

What the payments were for

  • Food & beverage$7,80791%
  • Education$7269%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,532 in reported general payments places this provider in the 70th percentile of 272 urology providers in Indiana.

See all urology providers in Indiana

Medicare billing

Part B allowed, 2024
$264,091
Medicare patients
1,069
Services billed
6,104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide77$1,125,706
NubeqaDarolutamide46$639,429
OrgovyxRelugolix78$289,827
MyrbetriqMirabegron52$47,729
GemtesaVibegron37$42,857
JatenzoTestosterone Undecanoate11$11,079
Tamsulosin Hcl670$7,498
Silodosin49$3,501
Oxybutynin Chloride ErOxybutynin Chloride107$2,954
Testosterone28$2,454
NitrofurantoinNitrofurantoin Macrocrystal71$2,345
Finasteride197$1,897
Methenamine Hippurate22$1,295
Dutasteride40$1,239
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst67$1,155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$828$1,125,70677 claims
BayerNubeqa$456$639,42946 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$827$332,684115 claims
Astellas Pharma US IncMyrbetriq$1,173$47,72952 claims
Clarus Therapeutics Inc.Jatenzo$86$11,07911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 272 urology providers in Indiana.

Other urology in Rensselaer

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →